Pemigatinib is a medication being studied for its effectiveness in treating cholangiocarcinoma, a type of cancer that affects the bile ducts. It works by targeting specific genetic changes in the cancer cells, known as FGFR2 rearrangements, which can help slow down or stop the growth of the cancer.

Gemcitabine is a chemotherapy drug used to treat various types of cancer, including cholangiocarcinoma. It works by interfering with the DNA of cancer cells, preventing them from growing and dividing.

Cisplatin is another chemotherapy medication that is often used in combination with other drugs like gemcitabine. It helps to kill cancer cells by damaging their DNA, which can lead to the death of these cells.

Cholangiocarcinoma – Cholangiocarcinoma is a type of cancer that forms in the bile ducts, which are the tubes that carry bile from the liver to the gallbladder and small intestine. It is a rare disease that can occur in different parts of the bile duct system, either inside the liver (intrahepatic) or outside the liver (extrahepatic). The disease often progresses slowly, with symptoms appearing only in the later stages, which can include jaundice, abdominal pain, and weight loss. As the cancer grows, it can block the bile ducts, leading to a buildup of bile in the liver and causing liver damage. The progression of cholangiocarcinoma can vary, but it typically involves the spread of cancer cells to nearby tissues and organs.